CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Q4 2024 Revenue: $164,000, down from $299,000 in Q4 2023.
Full Year 2024 Revenue: $515,000, down from $11 million in 2023.
Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023.
Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023.
Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023.
Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023.
Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023.
Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023.
Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023.
Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023.
Cash and Cash Equivalents (Dec 31, 2024): $11.9 million.
Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023.
Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023.
Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023.
Warning! GuruFocus has detected 4 Warning Signs with CLGN.
Release Date: March 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate.
The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery.
CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement.
The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm.
CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology.
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023.
The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023.
GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year.
Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses.
The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships.
Q: When can we expect an update from AbbVie on their studies, and are there any anticipated milestone payments in 2025? A: AbbVie is currently reviewing interim results from the first cohort of patients in their dermal filler clinical trials. The next steps will be determined by AbbVie, and we will update the market accordingly. Recently, we received a $2 million payment from AbbVie following a development achievement, but we cannot estimate when the next milestone payment will occur. - Eran Rotem, Deputy CEO and CFO
Q: Can you provide details on the market potential and revenue expectations for the VergenixSTR product in Europe and Asia? A: VergenixSTR is intended for treating tendinopathy and has a market potential of 1% to 3% of the population. We are establishing a distribution network in Europe and Asia, and each country requires regulatory approval. We expect to start seeing sales next year, with the product offering a significant advantage over steroid injections. - Yehiel Tal, CEO
Q: What is the company's current cash position and burn rate, and how long will it last? A: As of December 31, 2024, we had $11.9 million in cash, not including a recent $2 million payment from AbbVie. Our cost reduction plan does not materially impact main development programs. We expect our cash to support operations through the second quarter of 2026, under conservative assumptions. - Eran Rotem, Deputy CEO and CFO
Q: What are the upcoming catalysts for CollPlant's proprietary programs? A: We plan to potentially launch a clinical trial for our photocurable dermal and soft tissue filler within two years. For our regenerative breast implant program, we aim to optimize the implant characteristics and clinical protocol to reach clinical trial readiness. We will also expand the distribution network for VergenixSTR in Europe and Asia and broaden our bioinks product offerings. - Yehiel Tal, CEO
Q: How is CollPlant planning to expand sales of its rhCollagen product? A: We plan to expand sales of our rhCollagen to selected customers that align with our business model. This expansion is part of our strategy to support various bioprinting technologies and advance potential partnership discussions. - Yehiel Tal, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Jim Cramer Highlights That Dollar Tree (DLTR) Has 'More Trouble With the Tariffs'
We recently published a list of . In this article, we are going to take a look at where Dollar Tree, Inc. (NASDAQ:DLTR) stands against other stocks that Jim Cramer discusses. Discussing the impact of tariffs on Dollar Tree, Inc. (NASDAQ:DLTR), Cramer stated: 'Discount retailers tend to do better when the consumers' feeling stretched thin, and you know the consumer's feeling that way. But Dollar General and Dollar Tree have behaved very differently after reporting earnings over the past couple days… Then today, Dollar Tree reported what I also thought was a pretty good quarter, but its stock got eviscerated, down 8%. What explains the disparity here?… The difference between these two comes down to what they had to say about their ability to control costs and offset the impact of, you bet, go ahead, the president's tariffs… A shopper browsing through a discount retailers merchandise aisle filled with a wide variety of items. Dollar Tree (NASDAQ:DLTR) runs discount retail stores that carry a wide variety of products. The selection includes consumables, home essentials, seasonal items, apparel, and electronics. Overall, DLTR ranks 8th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of DLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Was Jim Cramer Right About Meta Platforms, Inc. (META)?
We recently published a list of . In this article, we are going to take a look at where Meta Platforms, Inc. (NASDAQ:META) stands against other stocks that Jim Cramer discusses. A viewer asked if Meta Platforms, Inc. (NASDAQ:META) still had technological upside, particularly under CEO Mark Zuckerberg's leadership. In that older segment, Cramer expressed strong long-term optimism, suggesting Meta was investing in something bigger than the public could yet see. He responded with: 'I think there is. I mean, I think that they're going to be in competition in something we don't know yet. They're buying too many of the Nvidia cards for me to think they're just going to continue to be just Instagram and Facebook and WhatsApp. I think there's much more in store for us and I think you got to stay long that stock. It is not an expensive stock.' Cramer was right to call it an inexpensive stock. It's now up +39.66% since those comments. Meta Platforms, Inc. (NASDAQ:META) is a technology company that owns Facebook, Instagram, and WhatsApp, and is investing heavily in AI and virtual reality platforms like the Metaverse. When asked about the stock again recently, Cramer gave his blessing to buy it, saying: 'I like your thinking very much. I think Meta's having a great quarter. I also think that they are without a doubt the best advertising bet. What happens if he actually starts, Mark Zuckerberg starts to want to, let's say, monetize WhatsApp? Do you know how much that darn thing's worth? I think you got horse sense. Good level to buy.' A team of developers working in unison to create the company's messaging application. Overall, META ranks 6th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
35 minutes ago
- Yahoo
Informa TechTarget Announces Partnership with Outreach to Help Companies Build and Accelerate Sales Pipeline Through More Intelligent Prospecting
This powerful combination helps mutual customers drive better business outcomes by efficiently identifying and effectively engaging prospects in an active buying journey NEWTON, Mass., June 09, 2025--(BUSINESS WIRE)--TechTarget, Inc. ("Informa TechTarget") (Nasdaq: TTGT), global growth accelerator and leading provider of intent data and insights to the B2B technology sector, today announced a strategic partnership and integration with Outreach, the only workflow-first sales execution platform. The integration empowers mutual customers to connect the dots between active buyer research and sales engagement so they can book more meetings, drive better conversations, create more pipeline, and accelerate deal velocity. "Roughly 9 out of 10 initial conversations with BDRs never progress through the sales cycle. Our new integration addresses this challenge head-on by fueling the timely and relevant engagement required to maximize conversion and pipeline impact," said Jillian Coffin, Senior Vice President of Customer Enablement and Strategy, Informa TechTarget. "By automatically adding Informa TechTarget's Active Prospects directly into topically aligned Outreach sequences, reps can dramatically improve their ability to connect with warm contacts when they're actively researching relevant topics and solutions." The new integration empowers sales teams to: Streamline workflows between Priority Engine, Informa TechTarget's proprietary purchase intent data platform, and Outreach to maximize sales efficiency Instantly add Active Prospects directly into relevant Outreach sequences with one click Automatically export Active Prospects to topically aligned Outreach sequences on a weekly basis Key benefits of this strategic partnership include: Increased efficiency and improved focus: Informa TechTarget's precise, person-level intent data helps reps more quickly identify and prioritize prospects with demonstrated solution interest so they can focus their efforts squarely on accounts and prospects showing active buying behavior. Timely engagement: Informa TechTarget continuously identifies new prospects from in-market accounts who are actively researching relevant topics across our network and delivers these permissioned buyers directly to Outreach. These automated workflows improve success by reducing the time to get from intent signal to outreach, enabling reps to engage prospects while they are actively researching and get into deals earlier. Improved conversion: Informa TechTarget delivers deep, real-time insights into the specific needs, pain points, and current topics of interest for each individual buyer who is actively researching on their topically relevant editorial communities. With this contextual intelligence at their fingertips, sellers can personalize every touchpoint based on a prospect's demonstrated interests and drive meaningful conversations that increase conversion to opportunity. The Informa TechTarget-Outreach integration is available now to current Priority Engine Sales subscribers at no additional cost. Customers must have both a Priority Engine Sales subscription and an Outreach license to utilize the integration. To learn more, click here. About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc d/b/a Informa TechTarget. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Garrett MannVice President of Corporate CommunicationsInforma Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
